Candidiasis currently exhibits a pipeline with 22 drug candidates by P&S Market Research.
The study analyzed that the candidiasis therapeutics pipeline comprises approximately 22 drug candidates in different stages of development.
As per the findings of the research, most of the candidiasis drug candidates are being developed to be administered by oral route.
Explore Report Description at: www.psmarketresearch.com/market-an…pipeline-analysis
Matinas Biopharma Holdings, Inc. is using Cochleate technology platform for the development of their drug candidates.
The technology platform is a lipid-crystal nano-particle targeted drug delivery system, that offers a drug delivery solution with differentiating and disruptive features including oral availability, multi-organ protection, enhanced safety and targeted delivery to the site of the infection and inflammation along with the ability to effectively penetrate the tissues.
The research found that various companies received many designations from the U.S. Food and Drug Administration (USFDA) for the development of candidiasis therapeutics pipeline.
In May 2016, USFDA granted the orphan drug designation to SCY-078 for the treatment of invasive candida infections, including candidemia.
Explore Report at: www.psmarketresearch.com/market-an…sis/report-sample
Some of the key players developing drugs for the treatment of candidiasis include Seren Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc., and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information:Make an Inquiry about this report HERE!